Abbott India Limited has announced the signing of a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited to market and distribute Vonoprazan in India under the brand name “Vonefi.” This agreement marks a significant step in enhancing the availability of innovative gastrointestinal therapies in the country.
Vonoprazan, a Potassium Competitive Acid Blocker (PCAB), addresses severe acid-related disorders such as reflux esophagitis through a once-daily dose. This novel molecule offers a significant improvement over current treatments for reflux esophagitis, which often require multiple doses to be effective, particularly in severe cases. As a first-of-its-kind therapy, Vonoprazan is expected to simplify treatment regimens and improve patient compliance, ultimately leading to better management of Gastroesophageal Reflux Disease (GERD).
With this agreement, Abbott, a leader in the gut health space, aims to make this advanced therapy accessible to more patients across India, reinforcing its commitment to providing cutting-edge healthcare solutions. The introduction of Vonefi is poised to benefit numerous individuals suffering from severe acid-related disorders by offering a more convenient and effective treatment option.
